CureLab Oncology

CEO Dr. Alexander Shneider presented clinical and preclinical findings on plasmid-based immunotherapy for cancer and inflammation at the Immuno-Oncology Summit.

Peer-reviewed study in Frontiers in Veterinary Science reports high efficacy of plasmid therapy in reducing osteoarthritis pain in dogs, with no significant side-effects.

Feature on open-label pilot study showing that plasmid DNA therapy provided significant pain relief in dogs with osteoarthritis, with implications for non-opioid pain management.

Article explored the translational promise of gene therapy resetting aging mesenchymal stem cells for canine arthritis and possible human application.

Collaborative review highlights therapeutic opportunities of DNA plasmid for inflammatory and cancer indications in domestic animals.

DNA plasmid therapy designated as a biologic veterinary product by the European Medicines Agency, outlining a regulatory path for EU market entry.

Presentation covers the mechanism of plasmid DNA therapy in remodeling the tumor microenvironment and modulating immune infiltration; evidence presented across cancer and chronic inflammation contexts.

Gene and anti-inflammation therapy patents granted in the USA, Europe, Asia, Latin America, and additional regions.

Secured exclusive global rights for all veterinary applications of gene therapy intellectual property derived from human-focused research.

Received $3 million investment to advance R&D and regulatory programs.